All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
ICML 2019 | How will front-line use of polatuzumab vedotin influence patient outcomes in DLBCL?
Bookmark this article
During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Hervé Tilly from CLCC Henri Becquerel, Rouen, FR, about how front-line use of polatuzumab vedotin might influence patient outcomes in diffuse large B-cell lymphoma (DLBCL).
Hervé Tilly describes how the study investigated the compound in combination with R-CHOP, and how the response rate of 89%, manageable safety profile, and a 77% complete response rate led to the proposal of an international, multi-center, double-blind, randomized phase II trial to compare the combination of R-CHOP and polatuzumab in 875 patients.
ICML 2019 | How will front-line use of polatuzumab vedotin influence patient outcomes in DLBCL?
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youRelated articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox